De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Jaguar Health Beheer

Beheer criteriumcontroles 3/4

De CEO Jaguar Health's is Lisa Conte, benoemd in Jun2013, heeft een ambtstermijn van 11.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 815.85K, bestaande uit 70.6% salaris en 29.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.002% van de aandelen van het bedrijf, ter waarde € 226.79. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 6.4 jaar.

Belangrijke informatie

Lisa Conte

Algemeen directeur

US$815.9k

Totale compensatie

Percentage CEO-salaris	70.6%
Dienstverband CEO	11.2yrs
Eigendom CEO	0.002%
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	6.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Lisa Conte's beloning veranderd ten opzichte van Jaguar Health's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$36m
Mar 31 2024	n/a	n/a	-US$38m
Dec 31 2023	US$816k	US$576k	-US$41m
Sep 30 2023	n/a	n/a	-US$40m
Jun 30 2023	n/a	n/a	-US$44m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$1m	US$603k	-US$47m
Sep 30 2022	n/a	n/a	-US$54m
Jun 30 2022	n/a	n/a	-US$54m
Mar 31 2022	n/a	n/a	-US$59m
Dec 31 2021	US$3m	US$527k	-US$53m
Sep 30 2021	n/a	n/a	-US$50m
Jun 30 2021	n/a	n/a	-US$46m
Mar 31 2021	n/a	n/a	-US$42m
Dec 31 2020	US$1m	US$500k	-US$39m
Sep 30 2020	n/a	n/a	-US$35m
Jun 30 2020	n/a	n/a	-US$39m
Mar 31 2020	n/a	n/a	-US$45m
Dec 31 2019	US$1m	US$500k	-US$45m
Sep 30 2019	n/a	n/a	-US$48m
Jun 30 2019	n/a	n/a	-US$43m
Mar 31 2019	n/a	n/a	-US$34m
Dec 31 2018	US$1m	US$480k	-US$32m
Sep 30 2018	n/a	n/a	-US$41m
Jun 30 2018	n/a	n/a	-US$30m
Mar 31 2018	n/a	n/a	-US$24m
Dec 31 2017	US$643k	US$440k	-US$22m

Compensatie versus markt: De totale vergoeding ($USD 815.85K ) Lisa } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 503.65K ).

Compensatie versus inkomsten: De vergoeding van Lisa is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Lisa Conte (65 yo)

11.2yrs

Tenure

US$815,854

Compensatie

Ms. Lisa A. Conte serves as a Scientific Advisor at Triton Funds LLC. She is a Former Member of Scientific Advisory Board at Triton Funds LLC. She founded Jaguar Health, Inc. (formerly known as Jaguar Anim...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Lisa Conte	Founder	11.2yrs	US$815.85k	0.0021% $ 226.8
Pravin Chaturvedi	Chief Scientific Officer & Chair of Scientific Advisory Board	2.4yrs	US$627.13k	0.00063% $ 67.1
Jonathan Wolin	Chief of Staff	5.8yrs	US$562.79k	0.00059% $ 62.8
Steven King	Chief of Sustainable Supply	9.9yrs	US$491.54k	0.00051% $ 54.3
Carol Lizak	Chief Financial Officer	4.4yrs	geen gegevens	0.00030% $ 31.9
Peter Hodge	Senior Director of Investor Relations	no data	geen gegevens	geen gegevens
Karen Brunke	Executive VP of Corporate & Business Development	2.9yrs	geen gegevens	geen gegevens
David Sesin	Chief Manufacturing Officer	no data	geen gegevens	geen gegevens
Ian Wendt	Chief Commercial Officer	3.7yrs	US$557.90k	geen gegevens
Massimo Radaelli	President of Jaguar International	less than a year	geen gegevens	geen gegevens
Catherine Collis	Senior Vice President of Growth Strategy	less than a year	geen gegevens	geen gegevens
Darlene Horton	Chief Medical Officer	no data	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1JA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Lisa Conte	Founder	11.2yrs	US$815.85k	0.0021% $ 226.8
Pravin Chaturvedi	Chief Scientific Officer & Chair of Scientific Advisory Board	7.3yrs	US$627.13k	0.00063% $ 67.1
James Bochnowski	Independent Chairman	10.5yrs	US$140.98k	0.00066% $ 70.3
John Micek	Independent Director	8.3yrs	US$101.68k	0.00038% $ 40.5
Anula Jayasuriya	Independent Director	2.1yrs	US$77.61k	0.00051% $ 54.3
Jonathan Siegel	Independent Director	6.4yrs	US$104.18k	0.00042% $ 44.7
Sandra Swain	Member of Scientific Advisory Board	1.6yrs	geen gegevens	geen gegevens
Kelly Shanahan	Scientific Advisory Board	1.4yrs	geen gegevens	geen gegevens
Stacey Tinianov	Member of Scientific Advisory Board	1.3yrs	geen gegevens	geen gegevens

6.4yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1JA wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.4 jaar).

Jaguar Health Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Recent updates

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care At American Society for Radiation Oncology Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024

Jaguar Health, Inc. Announces Issuance of New Hong Kong Patent Bolsters Ip Protection for Jaguar Health in the Treatment of Short Bowel Syndrome

Jaguar Health, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Napo Pharmaceuticals Announces Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders

Jaguar Health, Inc. Reports Phase 3 Ontarget Trial Results for Its Cancer Supportive Care Drug Crofelemer

Jaguar Health Announces 1-For-60 Reverse Stock Split in Order to Support Compliance with Nasdaq's Listing Standards

First quarter 2024 earnings released: US$0.058 loss per share (vs US$2.39 loss in 1Q 2023)

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. to Report Q1, 2024 Results on May 14, 2024

Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration

Jaguar Health Receives Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Full year 2023 earnings released: US$1.79 loss per share (vs US$36.18 loss in FY 2022)

Jaguar Health, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Jaguar Health Receives Notification Letter from The Nasdaq Stock Market LLC

Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health, Inc. announced that it has received $0.06 million in funding

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.38 loss per share (vs US$8.83 loss in 3Q 2022)

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New major risk - Financial position

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$8.82 loss in 2Q 2022)

Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome

Napo Pharmaceuticals Submits Investigational New Drug Application to FDA for MicroVillus Inclusion Disease

New major risk - Market cap size

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

First quarter 2023 earnings released: US$2.39 loss per share (vs US$30.17 loss in 1Q 2022)

Jaguar Health Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Jaguar Health, Inc. to Report Q1, 2023 Results on May 15, 2023

Jaguar Health, Inc. announced that it has received $1.86 million in funding

Jaguar Health, Inc. announced that it expects to receive $1.86 million in funding

Full year 2022 earnings released

Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

Jaguar Health, Inc. Provides Updates Regarding its Focus on Rare and Orphan Disease Indications in the U.S. & Europe

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (Cid) in Breast Cancer Patients

European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. announced delayed 10-Q filing

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Jaguar Health, Inc. Announces Appointment of Pravin Chaturvedi as Chief Scientific Officer and Chair of the Scientific Advisory Board

Jaguar Health Regains Compliance with Nasdaq Bid Price Requirement

Jaguar Health Explores Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ Covid-19 Recovery Patients in Europe

Jaguar Health Got Letter from Nasdaq Staying Stipulation for Company to Comply with Minimum Bid Price Requirement by Dec. 23

New 90-day high: €0.40

Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Plan to Study, Develop and Commercialize Crofelemer, the Company’s Novel Proprietary Drug, for an Indication of Inflammatory Diarrhea, Initially in Europe

Revenue misses expectations

Third quarter 2020 earnings released: US$0.20 loss per share

Jaguar Health Receives Positive Nasdaq Listing Determination

New 90-day low: €0.24

Jaguar Health, Inc. Announces Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs and Quality Assurance

New 90-day low: €0.26

New 90-day low - €0.34

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd